• Linagliptin (BI-1356) in Tau Assay Workflows

  2026-09-15

  Use Linagliptin (BI-1356) as an orthogonal pharmacology comparator when testing tau Ser356 biology in mouse and human brain-slice models. This workflow separates NUAK-linked effects from broader tissue-protective or stress-related responses while preserving the reference study’s emphasis on cell context and assay selection.

• ML365 and Hippocampal NLRP3 in Aged Mice

  2026-09-15

  A 2024 Brain Research study reports that ML365 pretreatment improves postoperative cognitive impairment in aged mice while reducing hippocampal NLRP3 inflammasome signaling, pathological injury, and plasma malondialdehyde. The work provides a preclinical bridge between two-pore-domain potassium channel pharmacology and postoperative neuroinflammation, while leaving direct TASK1 target engagement and translational efficacy to future studies.

• EZ Cap™ OVA mRNA: Specs, Uses & Workflow

  2026-09-14

  EZ Cap™ OVA mRNA is a 1,416-nucleotide, poly(A)-tailed Ovalbumin mRNA designed for immunology, gene expression studies, and vaccine development research. Its Cap 1 structure and reported 90–99% capping efficiency support controlled expression, but delivery conditions still determine cellular uptake and immune outcomes.

• RNAi Screen Identifies SARS-CoV-2 Release Factors

  2026-09-14

  Kerr et al. designed an arrayed, druggable-genome RNAi screen that measures SARS-CoV-2 production at multiple stages, addressing the early-replication bias of many host-factor studies. The work identifies Rab11a-linked vesicular transport as a conserved proviral pathway and shows that pharmacological CDK9 inhibition can suppress viral release, supporting further investigation of host-directed antiviral mechanisms.

• Fungal IAA, DOPE, and Ferroptotic Conidial Death

  2026-09-13

  The 2026 Molecular Plant Pathology study shows that Magnaporthe oryzae-derived indole-3-acetic acid promotes iron accumulation, lipid peroxidation, and ferroptotic death in developing conidia. Mutant and phosphatidylethanolamine-rescue experiments connect IAA-dependent lipid metabolism with appressorium formation and rice blast pathogenicity, while also implicating autophagy through ATG8 regulation.

• SM-102 for LNP mRNA Delivery: Workflow Guide

  2026-09-12

  SM-102 supports lipid nanoparticle workflows for both mRNA vaccine development and emerging localized therapeutic applications. This guide translates formulation principles, assay choices, and troubleshooting lessons from an intravesical p21 mRNA study into practical, evidence-aware laboratory workflows.

• Predictive siRNA Codelivery with Netarsudil

  2026-09-11

  Slaughter et al. developed a quantitative screening and machine-learning framework to predict which ionizable drugs can complex siRNA and support nanoparticle encapsulation. Netarsudil (AR-13324) emerged as a high-performing candidate and enabled CTGF siRNA delivery in fibrotic human trabecular meshwork cells, linking drug chemistry with a measurable cytoskeletal phenotype.

• Axitinib (AG 013736) Assay Workflows

  2026-09-11

  A practical guide to using Axitinib (AG 013736) in VEGFR-focused angiogenesis, signaling, and cancer cell assays. Learn how to separate growth suppression from cell killing, control DMSO and solubility variables, and translate pathway-level results into xenograft study plans.

• 5-Aminolevulinic acid HCl: Flux-Aware Assays

  2026-09-10

  Learn how 5-Aminolevulinic acid HCl can function as a controlled pathway-entry perturbation rather than a simple heme supplement. This article connects precursor flux, Salmonella immune evasion, assay interpretation, and translational cancer research while defining critical experimental limitations.

• EdU Imaging Kits (488) in UCMSC Senescence

  2026-09-10

  EdU Imaging Kits (488) connect S-phase DNA synthesis measurement with mechanistic studies of senescence in preeclampsia-derived umbilical cord mesenchymal stem cells. This guide explains how to design, interpret, and validate an EdU cell proliferation assay without confusing DNA replication with complete cell division.

• Angiotensin I: From RAS Precursor to Assay Control

  2026-09-09

  Angiotensin I is more than an intermediate in the renin-angiotensin system: it is a controllable substrate for dissecting peptide conversion, receptor biology, and antihypertensive drug screening. This guide explains how A1006 supports rigorous cardiovascular, neuroendocrine, and cross-domain assay design while defining what recent spike–receptor research does—and does not—show.

• ARCA EGFP mRNA for Transfection Workflow Control

  2026-09-09

  ARCA EGFP mRNA provides a fast, direct fluorescence readout for comparing delivery conditions, cell handling, and protein expression in mammalian systems. Its capped, polyadenylated design also makes it useful for qualifying emerging lipid nanoparticle workflows before committing valuable therapeutic mRNA cargo.

• BFH772 (VEGFR2 inhibitor): Workflow Guide

  2026-09-08

  BFH772 provides target-focused modulation of VEGFR2 for biochemical, cellular, and tumor angiogenesis research where selective pathway inhibition is required. It is not appropriate for water-based workflows without a validated solvent strategy, broad-spectrum kinase profiling, or direct clinical interpretation of product-dossier findings.

• 5-(N,N-dimethyl)-Amiloride NHE1 Workflow

  2026-09-08

  5-(N,N-dimethyl)-Amiloride hydrochloride provides a practical way to test how Na+/H+ exchange affects intracellular pH, sodium handling, and endothelial barrier behavior. This workflow connects mechanistic ion-transport assays with ischemia-reperfusion injury protection and cardiac contractile dysfunction research while clearly separating established product properties from proposed sepsis applications.

• NIH/3T3 Cells: Culture and QC Guide

  2026-09-07

  NIH/3T3 Cells provide an adherent mouse fibroblast model for routine culture, cell transfection studies, viral proliferation research, and oncogene research. This guide covers recovery, expansion, assay setup, and quality control, while noting that the product dossier does not establish quantitative performance, virus permissiveness, or clinical applicability.

8500 records 1/567 page Next 12345 下5页 Last page